The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk

NCT04562467 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Cardiovascular Diseases
Cardiovascular Risk Factor
Triglycerides High
Diabetes Mellitus, Type 2

Interventions

DRUG: Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]

Sponsor

Canadian Medical and Surgical Knowledge Translation Research Group

Collaborators

[object Object]
[object Object]
[object Object]